Rare and Orphan Disease Trials

Building Ethical Frameworks for Emergency Access to Rare Therapies

Posted on digi By digi

For patients with rare and life-threatening conditions, time is often the most precious resource. When no approved therapies exist, compassionate use or expanded access to investigational products becomes the only hope. Ethical frameworks ensure that such emergency access is granted fairly, transparently, and with due consideration of both risks and potential benefits. Unlike standard clinical trial enrollment, emergency access prioritizes urgent patient need over controlled study design, creating significant ethical and regulatory challenges.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials

How Drug Repurposing Transformed a Rare Disease Treatment Landscape

Posted on digi By digi

Developing new medicines for rare diseases has historically faced significant challenges: small patient populations, high research costs, and uncertain returns on investment. Drug repurposing—also called repositioning—has emerged as a pragmatic solution, leveraging existing compounds with established safety profiles for new therapeutic uses. This approach drastically reduces development timelines, costs, and risks, offering a lifeline for patients with unmet medical needs. In rare disease research, where urgency is high and patient numbers are low, repurposing can transform treatment landscapes in record time.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Differences Between U.S. and EU Rare Disease Regulatory Pathways

Posted on digi By digi

Rare diseases pose significant challenges in clinical research, including small patient populations, limited natural history data, and high development costs. To encourage innovation, both the United States and European Union offer regulatory incentives through distinct frameworks: the U.S. FDA’s Orphan Drug Act (1983) and the EU Orphan Regulation (EC No 141/2000). While both aim to facilitate development and approval of rare disease therapies, they differ in eligibility criteria, application processes, and post-approval benefits.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Implementing Risk-Based Monitoring in Rare Disease Trials

Posted on digi By digi

Rare disease trials face unique challenges that make traditional, intensive on-site monitoring inefficient and often unsustainable. Small patient populations, dispersed across numerous global sites, mean fewer patients per site and higher operational costs. Moreover, these studies often involve complex endpoints, novel therapies, and high protocol sensitivity—all demanding focused oversight.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Data Ownership and Consent in Rare Disease Research

Posted on digi By digi

Data is the cornerstone of rare disease research. With small patient populations, each data point—whether from a clinical trial, registry, or biobank—carries immense scientific and clinical value. However, questions about who owns this data, how it can be used, and what role patient consent plays remain complex and often contested. In rare disease contexts, where patients and families are deeply engaged in research, ensuring transparent and ethical data governance is paramount.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials

Success Story: Enzyme Replacement Therapy in Lysosomal Storage Disorders

Posted on digi By digi

Lysosomal storage disorders (LSDs) are a group of more than 50 inherited metabolic conditions caused by enzyme deficiencies that prevent the breakdown of specific substrates within lysosomes. These undigested molecules accumulate in cells, leading to multi-organ dysfunction and progressive disability. Examples include Gaucher disease, Fabry disease, and Pompe disease, each associated with severe morbidity and reduced life expectancy. Before the advent of enzyme replacement therapy (ERT), treatment options were limited to supportive care, palliative interventions, and in some cases, bone marrow transplantation with variable success rates.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Expedited Review Mechanisms for Rare Disease Clinical Trials in Asia-Pacific

Posted on digi By digi

As global pharmaceutical companies expand clinical research into emerging markets, the Asia-Pacific (APAC) region has gained increasing relevance in rare disease trials. Several countries in APAC—including Japan, South Korea, Australia, Singapore, and China—have introduced expedited review mechanisms to facilitate the development and approval of therapies for orphan and ultra-rare conditions. These programs aim to address unmet medical needs by shortening regulatory timelines and improving trial feasibility in diverse populations.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Ethical Recruitment Practices in Low-Income Countries for Rare Disease Trials

Posted on digi By digi

As rare disease clinical trials expand worldwide, sponsors and investigators are increasingly turning to low- and middle-income countries (LMICs) to recruit participants. These regions may offer unique genetic diversity, treatment-naïve populations, or specific disease prevalence. However, recruiting in LMICs raises critical ethical challenges, particularly concerning equity, patient safety, and exploitation risks.
Click to read the full article.

Ethics & Patient Engagement, Rare and Orphan Disease Trials

Managing Long-Term Sample Storage for Rare Disease Research

Posted on digi By digi

Long-term biological sample storage is an essential component of rare disease clinical trials. Due to the small number of patients and the progressive nature of many rare diseases, biospecimens often represent irreplaceable data sources. Properly stored samples may be reanalyzed years later for biomarker discovery, regulatory re-submissions, or personalized medicine approaches.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Regulatory Compliance for Cross-Border Rare Disease Studies

Posted on digi By digi

Rare disease trials often require collaboration across multiple countries to achieve adequate patient recruitment. This cross-border approach, while necessary, introduces a host of regulatory challenges—from differing clinical trial application (CTA) processes to varied ethics committee expectations, import/export rules, and safety reporting requirements.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks